X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
splenomegaly - prevention & control (113) 113
animals (85) 85
mice (71) 71
female (58) 58
male (57) 57
humans (45) 45
index medicus (33) 33
splenomegaly - etiology (25) 25
mice, inbred c57bl (22) 22
immunology (20) 20
disease models, animal (17) 17
adult (16) 16
middle aged (16) 16
aged (14) 14
hematology (14) 14
mice, inbred balb c (13) 13
treatment outcome (13) 13
leukemia, experimental - prevention & control (12) 12
oncology (12) 12
time factors (12) 12
spleen - pathology (11) 11
cells, cultured (10) 10
child, preschool (10) 10
follow-up studies (10) 10
splenomegaly - pathology (10) 10
child (9) 9
friend murine leukemia virus - drug effects (9) 9
splenomegaly - immunology (9) 9
activation (8) 8
adolescent (8) 8
expression (8) 8
hepatomegaly - prevention & control (8) 8
malaria (8) 8
mice, knockout (8) 8
pharmacology & pharmacy (8) 8
spleen (8) 8
splenomegaly (8) 8
anemia (7) 7
mice, inbred dba (7) 7
mice, inbred strains (7) 7
spleen - immunology (7) 7
splenomegaly - chemically induced (7) 7
aged, 80 and over (6) 6
analysis (6) 6
cohort studies (6) 6
disease (6) 6
dose-response relationship, drug (6) 6
friend murine leukemia virus (6) 6
immunosuppression (6) 6
immunosuppressive agents - therapeutic use (6) 6
infant (6) 6
leukemia (6) 6
leukemia, experimental - drug therapy (6) 6
lupus nephritis - prevention & control (6) 6
lymphatic diseases - prevention & control (6) 6
mice, transgenic (6) 6
primary myelofibrosis - drug therapy (6) 6
rats (6) 6
retrospective studies (6) 6
splenomegaly - genetics (6) 6
tropical medicine (6) 6
antibodies (5) 5
apoptosis - drug effects (5) 5
b-lymphocytes - immunology (5) 5
children (5) 5
gastrointestinal hemorrhage - prevention & control (5) 5
health aspects (5) 5
hemic and lymphatic diseases (5) 5
inflammation (5) 5
lupus nephritis - pathology (5) 5
medicine, research & experimental (5) 5
organ size (5) 5
public, environmental & occupational health (5) 5
rauscher virus - drug effects (5) 5
research (5) 5
research article (5) 5
splenomegaly - complications (5) 5
t-lymphocytes - immunology (5) 5
administration, oral (4) 4
anemia - prevention & control (4) 4
antineoplastic agents - therapeutic use (4) 4
antiviral agents - pharmacology (4) 4
apoptosis (4) 4
article (4) 4
bone marrow - pathology (4) 4
cd4-positive t-lymphocytes - immunology (4) 4
cell biology (4) 4
erythropoiesis - drug effects (4) 4
flow cytometry (4) 4
graft vs host reaction - drug effects (4) 4
hematocrit (4) 4
immunosuppressive agents - pharmacology (4) 4
induction (4) 4
infection (4) 4
kidney glomerulus - pathology (4) 4
leukemia, experimental - immunology (4) 4
lupus nephritis - genetics (4) 4
lupus nephritis - immunology (4) 4
medicine & public health (4) 4
mice, inbred c3h (4) 4
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (108) 108
Chinese (2) 2
German (2) 2
Italian (2) 2
French (1) 1
Japanese (1) 1
Portuguese (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Brain, Behavior, and Immunity, ISSN 0889-1591, 2015, Volume 51, pp. 154 - 168
Highlights • Classical benzodiazepines ameliorated stress-induced neuroimmune responses. • Lorazepam and clonazepam blocked stress-induced neuroinflammatory... 
Psychiatry | Allergy and Immunology | Anxiety-like behavior | Social avoidance | Social defeat | Benzodiazepines | Psychosocial stress | Microglia | ACTIVATION | MONOCYTE TRAFFICKING | ANXIETY | PSYCHIATRY | IMMOBILIZATION STRESS | RECEPTOR | AGED MICE | IMMUNOLOGY | INTERLEUKIN-6 | NEUROSCIENCES | DEFEAT STRESS | GABA | GLUCOCORTICOID RESISTANCE | Anti-Anxiety Agents - administration & dosage | Male | Hippocampus - drug effects | RNA, Messenger - metabolism | Stress, Psychological - immunology | Hematopoiesis - drug effects | Microglia - immunology | Granulocytes - drug effects | Interleukin-6 - blood | Splenomegaly - etiology | Behavior, Animal - drug effects | Corticosterone - blood | Hypothalamus - drug effects | Bone Marrow - drug effects | Hypothalamus - immunology | Clonazepam - administration & dosage | Hippocampus - immunology | Microglia - drug effects | Mice, Inbred C57BL | GABA Modulators - administration & dosage | Splenomegaly - prevention & control | Lorazepam - administration & dosage | Corticotropin-Releasing Hormone - metabolism | Anxiety - immunology | Brain - drug effects | Monocytes - drug effects | Animals | Mice | CD11b Antigen - metabolism | Brain - immunology | Anxiety - etiology | Stress, Psychological - complications | Stress management | Lorazepam | Clonazepam | psychosocial stress | benzodiazepines | anxiety-like behavior | social avoidance | social defeat | microglia
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 2010, Volume 9, Issue 7, pp. 1945 - 1955
Journal Article
Journal Article
Journal Article
Arthritis Research and Therapy, ISSN 1478-6354, 11/2012, Volume 14, Issue 6, pp. R243 - R243
Journal Article
American Journal of Hematology, ISSN 0361-8609, 02/2017, Volume 92, Issue 2, pp. 187 - 195
Journal Article
Journal of Cellular and Molecular Medicine, ISSN 1582-1838, 11/2013, Volume 17, Issue 11, pp. 1385 - 1396
Aberrant JAK2 signalling plays a central role in myeloproliferative neoplasms (MPN). JAK2 inhibitors have proven to be clinically efficacious, however, they... 
BEZ235 | PI3K pathway | in‐vivo | JAK2 | myeloproliferative disorders | in-vivo | Myeloproliferative disorders | MEDICINE, RESEARCH & EXPERIMENTAL | CELLS | POLYCYTHEMIA-VERA | PRIMARY MYELOFIBROSIS | ESSENTIAL THROMBOCYTHEMIA | JAK2V617F | CELL BIOLOGY | THERAPEUTIC TARGET | MUTATION | MICE | INHIBITOR | EXPRESSION | Neoplasm Transplantation | Myeloproliferative Disorders - enzymology | TOR Serine-Threonine Kinases - metabolism | Apoptosis - drug effects | Humans | Imidazoles - administration & dosage | Hematologic Neoplasms - enzymology | Phosphatidylinositol 3-Kinases - metabolism | Mutation, Missense | Molecular Targeted Therapy | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Quinolines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - pharmacology | TOR Serine-Threonine Kinases - antagonists & inhibitors | Janus Kinase 2 - metabolism | Hematopoietic Stem Cells - physiology | Inhibitory Concentration 50 | Female | Janus Kinase 2 - antagonists & inhibitors | Hematopoietic Stem Cells - drug effects | Janus Kinase 2 - genetics | Splenomegaly - prevention & control | Mice, Transgenic | Myeloproliferative Disorders - drug therapy | Mice, SCID | Drug Synergism | Pyrazoles - administration & dosage | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | K562 Cells | Hematologic Neoplasms - drug therapy | Cell Proliferation - drug effects | Mice | Drug Screening Assays, Antitumor | Analysis | Tumors | TOR protein | Cell culture | Leukemia | Kinases | Experiments | Synergism | Neoplasms | Proteins | Signal transduction | Cell growth | Histopathology | Pathways | Janus kinase 2 | Cell cycle | Janus kinase | Inhibition | Drug dosages | Spleen | Cell survival | Cytokines | Immunodeficiency | Reticulocytes | Progenitor cells | 1-Phosphatidylinositol 3-kinase | Signaling | Inhibitors | Cell lines | Stem cells | Mutation | Apoptosis | Original
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 11/2015, Volume 10, Issue 11, p. e0143136
Oxaliplatin-based chemotherapy is widely used to treat advanced colorectal cancer (CRC). Sinusoidal obstruction syndrome (SOS) due to oxaliplatin is a serious... 
LEUCOVORIN | VONWILLEBRAND-FACTOR | HEPATIC VENOOCCLUSIVE DISEASE | PLASMA-LEVELS | BEVACIZUMAB | MULTIDISCIPLINARY SCIENCES | FACTOR MULTIMERS | PATHOLOGICAL RESPONSE | STEM-CELL TRANSPLANTATION | FLUOROURACIL | METASTATIC COLORECTAL-CANCER | Blood Platelets - pathology | Bevacizumab - therapeutic use | Autoantibodies - blood | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Hepatic Veno-Occlusive Disease - prevention & control | Splenomegaly - pathology | Hepatic Veno-Occlusive Disease - blood | Organoplatinum Compounds - administration & dosage | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Platelet Glycoprotein GPIIb-IIIa Complex - metabolism | Splenomegaly - blood | Splenomegaly - etiology | Angiogenesis Inhibitors - therapeutic use | Adult | Female | Hepatic Veno-Occlusive Disease - pathology | Thrombosis - blood | Thrombosis - prevention & control | Blood Platelets - drug effects | von Willebrand Factor - metabolism | Hepatic Veno-Occlusive Disease - etiology | Colorectal Neoplasms - blood | Endothelial Cells - metabolism | Splenomegaly - prevention & control | Disease Progression | Thrombosis - pathology | Aspartate Aminotransferases - blood | Blood Platelets - metabolism | Thrombosis - etiology | Aged | Colorectal Neoplasms - pathology | Endothelial Cells - pathology | Neoplasm Staging | Organoplatinum Compounds - adverse effects | Endothelial Cells - drug effects | Complications and side effects | Care and treatment | Chemotherapy | Usage | Von Willebrand factor | Colorectal cancer | Influence | Research | Health aspects | Cancer | Blood transfusions | Splenomegaly | Disease | Liver | Colorectal carcinoma | Antibodies | Metastasis | Shear stresses | Cancer therapies | Molecular weight | Bevacizumab | Oxaliplatin | Blood platelets | Surgery | Bone marrow | Vascular endothelial growth factor | Stretching | Congenital diseases | Patients | Thrombosis | Endothelial cells | Response rates | Stem cells | Aspartate aminotransferase | Health risk assessment | Platelets
Journal Article